Tizanidine Tablet
Product Images NDC 68084-775

10 FDA label images from American Health Packaging · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 68084-775). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2 mg Tizanidine Tablet Blister

2 mg Tizanidine Tablet Blister
Packaging label for Tizanidine Tablet USP 2 mg, oral tablet by American Health Packaging. The label includes the drug name, strength (2 mg), lot number, and expiration date (02/19). The label shows multiple identical panels with barcode and manufacturer information from Columbus, OH.*
FDA Label Image

2 mg Tizanidine Tablets Carton

2 mg Tizanidine Tablets Carton
This image shows a drug facts label for Tizanidine Tablets USP, 2 mg strength, in a package of 30 tablets. It includes dosage information, storage instructions (store at 20° to 25°C with permitted excursions), and safety warnings such as not using the blister if torn. The label specifies the drug is distributed by American Health Packaging and contains identifiers like the NDC 68084-775-25.*
FDA Label Image

4 mg Tizanidine Tablet Blister

4 mg Tizanidine Tablet Blister
Packaging label for Tizanidine Tablet USP 4 mg by American Health Packaging. The label includes multiple copies arranged in two columns, each showing the product name, strength, dosage form, a barcode, an NDC number (00368804 645 11 2), and placeholder text for lot number and expiry date. Manufactured by American Health Packaging, Columbus, Ohio.*
FDA Label Image

4 mg Tizanidine Tablets Carton

4 mg Tizanidine Tablets Carton
Tizanidine Tablets, USP 4 mg oral tablets by American Health Packaging. The label indicates a package size of 100 tablets (10 x 10) with product NDC 68084-645-01. It includes a barcode and a note that these tablets are not interchangeable with Tizanidine Capsules. Storage instructions specify maintaining temperatures between 20°C to 25°C with permitted excursions from 15°C to 30°C.*
FDA Label Image

55111 0179 15 7f0ebf85

55111 0179 15 7f0ebf85
Tizanidine 4 mg white, oval tablet imaged from both sides. One side is scored, the other side is embossed with the imprint 'AH 4'. The tablet measures approximately 9 mm in length. Oral dosage form produced by American Health Packaging.*
FDA Label Image

55111 0180 15 D31d69ab

55111 0180 15 D31d69ab
Tizanidine 2 mg or 4 mg oral tablets by American Health Packaging are white, capsule-shaped with an imprint of 'R180' on one side and a score line on the other side. The image shows front and back views with size scale in millimeters.*
FDA Label Image

Figure 1

Figure 1
A line graph showing plasma tizanidine concentration (ng/mL) over time (hours from dosing) for 2 mg and 4 mg doses of tizanidine tablets and capsules. The graph compares absorption with and without food, illustrating concentration peaks within the first few hours post-dose and decline thereafter.*
FDA Label Image

Structural Formula

Structural Formula
Chemical structure diagram of Tizanidine Hydrochloride, showing a chlorinated benzothiadiazole ring linked to an imidazoline moiety. The image details atomic connectivity including nitrogen, sulfur, chlorine atoms, and hydrocarbon bonds.*
FDA Label Image

Fig2 (Fig2)

Fig2 (Fig2)
Line graph showing improvement in Ashworth score over 6 hours post-dose for 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis represents improvement in Ashworth score and the x-axis represents hours post-dose. The graph indicates the highest improvement occurs around 2 hours post-dose for tizanidine compared to placebo.*
FDA Label Image

Fig3 (Fig3)

Fig3 (Fig3)
A line graph comparing improvement in Ashworth Score between tizanidine (mean dose 28.8 mg) and placebo at three timepoints: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). The graph includes error bars indicating variability around mean improvement scores for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.